27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The U.S. Food and Drug Administration issued an alert on issues discovered in ongoing studies of Merck & Co., Inc. (NYSE:MRK)’s Keytruda Roche’s Tecentriq, according to a headline from Bloomberg. Regulators reportedly found that some patients had decreased survival.
Why It’s Important
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Keytruda, which is already approved for the treatment of cancers such as melanoma, non-small cell lung cancer and Hodgkin lymphoma, is a considered a major opportunity for Merck. Updates on the drug are enough to move the stock and sway bearish experts.
A threat to Keytruda is notable for Merck, but it also carries implications for Bristol-Myers Squibb Co (NYSE:BMY), whose Opdivo competes for market share. BMO Capital Markets recently noted the drugs are “more similar than different.”
Merck shares initially fell 3 percent on the news, while Bristol Myers rose marginally.
What’s Next
The FDA has not yet published a report on the matter, but clarity on the alleged “issues” could help or hurt the rival drugmakers.
Related Links:
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.